Sanne Franck

Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly

Sebastian Neggers, Sanne Franck, Felix W.M. de Rooij et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 123 citations

Pharmacy, Endocrinology, Pharmacotherapy +14

In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas

Federico Gatto, Richard A. Feelders, Sanne Franck et al. · The Journal of Clinical Endocrinology & Metabolism · 2017 · 65 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression

Ammar Muhammad, Eva C Coopmans, Federico Gatto et al. · The Journal of Clinical Endocrinology & Metabolism · 2018 · 60 citations · Full text

Life Sciences, Endocrinology, Pharmacotherapy +16

Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant

Sanne Franck, Federico Gatto, Aart Jan van der Lely et al. · Neuroendocrinology · 2016 · 34 citations · Full text

Medicine, Endocrinology, Pharmacology +17

A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues

Sanne Franck, Tim I.M. Korevaar, Patrick Pétrossians et al. · European Journal of Endocrinology · 2017 · 24 citations · Full text

Pharmacy, Endocrinology, Pharmacokinetics +17